T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing a 6.3% beneficial ownership position in Charles River Laboratories International common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 3,010,619 shares of Charles River Laboratories common stock.
  • Percent of class: The 3,010,619 shares represent 6.3% of the class, according to the filing.
  • Sole voting power: T. Rowe Price disclosed sole voting power over 2,768,367 shares.
  • Sole dispositive power: The filing reports sole dispositive power over all 3,010,619 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering date: The event requiring this filing occurred on September 30, 2026.
  • Filer classification: T. Rowe Price Associates, Inc. is identified as an investment adviser (type "IA"), organized in Maryland.

T. Rowe Price's Disclosed Position in Charles River Laboratories

According to the Schedule 13G filed on November 16, 2026, T. Rowe Price Associates, Inc., an investment adviser headquartered at 1307 Point Street, Baltimore, MD 21231, reported beneficial ownership of 3,010,619 shares of Charles River Laboratories common stock (CUSIP 159864107). The filing identifies Charles River Laboratories' principal executive offices at 251 Ballardvale St, Wilmington, MA 01887. The position represents 6.3% of the outstanding class of common stock, as stated in the filing.

The filing discloses that T. Rowe Price holds sole voting power over 2,768,367 shares and sole dispositive power over all 3,010,619 shares. No shared voting or dispositive power is reported. The statement was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., and dated November 16, 2026.

The filing includes a certification stating that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." T. Rowe Price Associates, Inc. also "expressly denied" that the filing constitutes an admission of beneficial ownership, as stated in the filing's certifications section.

What Was Disclosed

T. Rowe Price Associates, Inc. filed a Schedule 13G disclosing beneficial ownership of 3,010,619 shares, or 6.3%, of Charles River Laboratories common stock, with a triggering event date of September 30, 2026, and filing date of November 16, 2026.